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Sequential study ofbone
mineral density in patients
with systemic lupus
erythematosus
A loss of bone mineral density has been
reported1`S in premenopausal women with
systemic lupus erythematosus (SLE), but its
pathogenesis is uncertain.4 Studies on the
sequential changes in bone mass in these
patients are scarce.35
Recently, we studied 74 premenopausal
women with SLE without any complications
or treatment (except for glucocorticoids) that
could interfere with bone mineral density.2
We excluded nine osteoporotic patients
according the established World Health
Organisation criteria,6 because they were on
treatment for low bone density. We repeated
the measurement of bone mass after 18
months in 25 consecutive patients, all of
whom had continued on glucocorticoid
treatment during this period.
Bone mineral density was measured in the
lumbar spine (L2-L4) and femoral neck
(FN) by dual energy x ray absorptiometry
(DXA), using a densitometer (Hologic QDR
1000). Measurement of the bone mineral
content, calibrating with the Hologic
X-calibre QDR-1 anthropomorphic spine
phantom of the known mineral content, was
accurate to 0.5%. The precision measure-
ment was better than 0.01 g cm-2 (coefficient
of variation = 1.0% at bone mineral density
1.0 g cm-2). Disease activity was assessed with
the University College Hospital/Middlesex
SLE scoring system,7 by a numerical score
graded from 1 to 4 (inactive to severely active
disease).
The results were expressed as the mean
(SD). For all conventional analyses we used
the SPSS/PC software package. A t test was
used and the correlations were calculated by
linear regression analysis. Results were
considered significant at P < 0.05.
At the time of the first densitometry, the
mean age was 31.7 (6.8) years, and disease
duration was 91 (64) months.
After 18 months there was no significant
decrease in bone mineral density, despite glu-
cocorticoid treatment (table), in either the
lumbar spine or the femoral neck. No
fractures were found. Serum calcium,
phosphorus, creatinine, and alkaline phos-
phatase, and 24 hour urine calcium and
phosphorus did not change during this
period.
Using linear regression, there was no
correlation between bone mineral density or
changes in bone mineral density and the
prednisone dose (cumulative and baseline).
We found no correlation between disease
duration or mean disease activity grade and
bone mineral density. No other correlations
with bone mineral density were found.
This study shows that in premenopausal
SLE patients lumbar and femoral bone min-
Characteristics of 25 patients at baseline and
after 18 months
Baseline (mean 18 months
(SD)) (mean (SD))
L2-L4 (g cm-2) 1.00 (0.09) 1.00 (0.1)*
F.neck (g cm-2) 0.80 (0.07) 0.79 (0.08)*
P.baseline (mg) 17 (2) 16 (9.4)
P.cumulative (g) 35 (2) 41 (5)
Activity grade 2.47 (0.4) 2.41 (0.5)
* All P values > 0.05 versus baseline.
eral density did not change with respect to
baseline values after 18 months, despite con-
tinuous glucocorticoid treatment (the mean
dose was 9.2 mg/day during the 18 months).
Recently, Pons et al 3 reported similar results
in a study of 31 premenopausal women
followed for a mean of 36.6 months. Kalla et
al 5 also found no changes in bone mineral
density in 56 SLE patients over 18 months.
The effect ofglucocorticoids on SLE osteo-
porosis is controversial.' We did not find any
correlation between prednisone dose and
bone mineral density in chronic steroid users.
The effects of glucocorticoids on the bone
mass are most pronounced early in the course
of steroid treatment.89 These data may partly
explain our results. Also, a multifactorial
action could explain the lack of correlation
between the dose of glucorticoids and bone
mineral density. Glucocorticoids may
paradoxically inhibit bone resorption that has
been stimulated by PGE2 or cytokines.' 01'
In conclusion, after 18 months there were
no significant decreases in bone mineral den-
sity in premenopausal SLE patients on
glucocorticoid treatment. The reported
reduction in bone mineral density in these
patients may occur at the onset of the disease.
Nevertheless, future studies to demonstrate a
small loss ofbone mineral density in SLE will
probably require more patients and a longer
period of study.
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Unilateral Heberden's
nodes in a case of
Erb-Duchenne paralysis
Referring to the letter by Etherington and
Spector ("Asymmetrical nodular osteoarthri-
tis in a patient with a hemiparesis", Annals of
the Rheumatic Diseases, November 1995, p
936), we would like to offer a contribution
based on our recent experience.
Although Stecher and Karnosh' assert that
apparent involution of Heberden's nodes on
the hemiplegic side should be attributed
exclusively to the effects of a reduction of soft
tissues, in spite of the existence of x ray
nodes, Forestier,2 Hench and McEwen,3 and
Thompson and Bywaters4 suggest a
"neurogenic protection" against nodes on the
affected side.
This particular characteristic of Heber-
den's and Bouchard' s nodes, was pointed out
both in hemiplegic subjects following a
central cerebral lesion as in the case of Eth-
erington and Spector5-or in upper limbs
affected by peripheral paralysis (obstetric
paralysis or traumatic interruption of a
nerve).
Our case is a 45 year old female who
presented with Erb-Duchenne paralysis and
Heberden's nodes limited to the healthy side,
while the affected arm shows a lack of
musculoskeletal development (radius, ulna,
carpus, metacarpus, and phalanges) (figure)
In analogy with what has been pointed out
in the case of rheumatoid arthritis and hemi-
plegia67 it is possible formulate several
hypotheses:
(1) A protective action of central or
peripheral neurological lesions with
respect to osteoarthritic or arthritic8
manifestations on the affected side,
through interruption of the central reflex
arc, which is responsible for the symmet-
ric lesions in rheumatoid arthritis and
osteoarthrosis.
(2) Attenuation of superimposed inflamma-
tion in osteoarthrosis by the conditioning
of the biochemical expression of the neu-
rogenic inflammation (mediated by
substance P, a neuropeptide which acts
specifically at low concentrations on
"formyl peptide" receptors; this leads to
the activation of polymorphonuclear
cells and is present both early and in
large quantities in inflammed syn-
ovium).9
(3) Not be ignored, in our opinion, is the
physiological decline of the propriocep-
tion in subjects of advancing age'0 and
the absence of the normal proprioceptive
stimuli linked to the "microtraumatic"
use of the hands which is limited only to
the affected hand. Such absence is also
presumably responsible for lack of node
production related to enthesitic ossifica-
tion at the distal phalanx level.
We agree with Etherington and Spector5
about the possibility that several valid
concepts relating to the protective effects of
neurological lesions, either central or periph-
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